Myrtle Beach, SCNCT07222488Now EnrollingIRB Ready

Bladder Cancer Clinical Trial in Myrtle Beach, SC

Access cutting-edge bladder cancer treatment through this phase 1/2 clinical trial at a research site in Myrtle Beach. Study-provided care at no cost to qualified participants.

Sponsored by Merck Sharp & Dohme LLC

Quick Self-Assessment

See if you qualify for this Myrtle Beach location

Preparing your pre-screening questions…

Expert Care in Myrtle Beach

Access bladder cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related bladder cancer treatment provided free

Apply for This Myrtle Beach Location

Check if you qualify for this bladder cancer clinical trial in Myrtle Beach, SC

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Myrtle Beach

    Convenient for SC residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Myrtle Beach site if eligible
  4. 4Begin participation

About This Bladder Cancer Study in Myrtle Beach

Researchers are looking for new ways to treat high-risk non-muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder and has not spread to the bladder muscle or outside of the bladder. In standard treatment for HR NMIBC, doctors first remove the tumor with a procedure called transurethral resection of the bladder tumor (TURBT). Researchers want to learn if using MK-3120, the study medicine, can treat HR NMIBC after TURBT. The goal of this study is to learn about the safety of MK-3120 and if people tolerate it.

Sponsor: Merck Sharp & Dohme LLC

Who Can Participate

Inclusion Criteria

Has histologically confirmed carcinoma in situ (CIS) +/- papillary high-risk non-muscle invasive bladder cancer (NMIBC), confirmed locally.
Is an individual whose most recent transurethral resection of bladder tumor (TURBT) was performed within 12 weeks before allocation and showed high-risk NMIBC histology. For individuals with papillary tumors (Ta and T1), a complete TURBT must have been performed, as characterized by attainment of a visually complete resection of all papillary tumors (Ta and T1).
Is either: a) Bacillus Calmette-Guérin (BCG)-naïve, defined as either having never received BCG or having received BCG more than 2 years before CIS +/- papillary high-risk NMIBC recurrence. Recurrence must be at least 24 months from the last exposure to BCG with evidence of complete response during the 2-year period post-BCG OR; b) BCG-exposed and received adequate BCG therapy and had recurrence of CIS +/- papillary high-risk NMIBC \>12 months but ≤24 months after the last BCG dose.
Human immunodeficiency virus (HIV)-infected participants must have well-controlled HIV on antiretroviral therapy.
Participants who are hepatitis B surface antigen positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load prior to allocation.
Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening.

Exclusion Criteria

Has history of or current locally advanced (ie, T2, T3, T4) or metastatic urothelial cancer (UC).
Has concurrent extravesical (ie, urethra, ureter, renal pelvis) non-muscle invasive UC or history of extravesical non-muscle invasive UC that recurred within the last 2 years.
Has active total bladder incontinence, active urinary tract infection, neurogenic bladder, or urethral stricture.
Has a condition that would prohibit normal voiding (or holding bladder voiding for 1 to 2 hours).
Has uncontrolled, significant cardiovascular disease or cerebrovascular disease, including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, prolongation of QTcF interval to \>470 ms, and/or other serious cardiovascular and cerebrovascular diseases within the 6 months preceding study intervention.
Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing.
HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.
Has known additional malignancy that is progressing or has required active treatment within the past 3 years.
Has known active central nervous system metastases and/or carcinomatous meningitis.
Has active infection requiring systemic therapy.
Has a history of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids, or has current pneumonitis/ILD.
Has not adequately recovered from major surgery or has ongoing surgical complications.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Myrtle Beach?

Yes, this clinical trial (NCT07222488) has an active research site in Myrtle Beach, SC that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Bladder Cancer Treatment Options in Myrtle Beach, SC

If you're searching for bladder cancer treatment options in Myrtle Beach, SC, this clinical trial (NCT07222488) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Myrtle Beach research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced bladder cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all bladder cancer clinical trials near you to find additional studies recruiting in your area.

More Bladder Cancer Trials in Myrtle Beach, SC

See all bladder cancer clinical trials recruiting in Myrtle Beach — not just this study.

Browse Bladder Cancer Trials in Myrtle Beach →

Browse More Trials by Condition

Bladder Cancer TrialsGallbladder Cancer TrialsAlzheimers Disease TrialsADHD TrialsAtopic Dermatitis TrialsAll Conditions →

Ready to Join in Myrtle Beach?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Myrtle Beach, SC